Articles from Augurex Life Sciences Corp.

Augurex Life Sciences Corp., a leader in the development of autoimmune-based diagnostics, today announced the upcoming launch of the 14-3-3eta test, approved as JOINTstat® in Canada and the UK, through Sonic Reference Laboratory, a division of Sonic Healthcare USA. Beginning December 15, 2025, the test will be available to healthcare providers across the United States as part of Sonic’s diagnostic portfolio. The 14-3-3eta test improves early detection and management of rheumatoid arthritis (RA), providing clinicians with a powerful tool to enhance care and optimize outcomes.

Augurex Life Sciences Corp., a leader in the development of autoimmune diagnostic tests, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the SPINEstat® 14-3-3eta Autoantibody Multiplex Immunoassay Test (approved as SPINEstat® in Canada and the United Kingdom) for the diagnosis of patients with axial spondyloarthritis (axSpA). The designation recognizes the potential of this first-in-class diagnostic test to address a large unmet need in the early and accurate differentiation of axSpA within the broader chronic back pain population.

Augurex Life Sciences Corp., a leader in autoimmune-based diagnostics, today announced an agreement with MitogenDx, a Canadian specialty laboratory focused on autoimmune and rheumatology diagnostic testing. Under this agreement, MitogenDx will offer the JOINTstat® blood test, expanding access to advanced rheumatoid arthritis (RA) diagnostic testing and disease monitoring for clinicians and patients across Canada.

Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that Health Canada has approved SPINEstat™, a first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), as a Class II medical device. By detecting auto-antibodies to the 14-3-3eta protein, SPINEstat™ provides an important new clinically validated and objective biomarker to aid in the early and accurate diagnosis of axSpA.

Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it has formed a nonexclusive agreement with Quest Diagnostics, a leading provider of diagnostic information services, under which Quest will validate and offer a lab-developed test based on the Augurex 14-3-3η (eta) biomarker in the United States.

Augurex Life Sciences Corp. (“Augurex”) today announced the launch of Anti-14-3-3eta Multiplex Analyte Specific Reagents (ASRs), supporting the development of a first-in-class diagnostic test that assists clinicians in the diagnosis of axial spondyloarthritis (axSpA). New Day Diagnostics in Knoxville, TN, developed the diagnostic test using the Anti-14-3-3eta Multiplex ASRs as components and now offers the test through physician order only. This novel diagnostic test is designed to empower clinicians to identify axSpA at an earlier stage, potentially addressing the often-lengthy diagnostic delay and improving outcomes for patients.

Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced its participation at the American College of Rheumatology (ACR) Convergence 2024, taking place in Washington, DC from November 14-19. Augurex will present a poster and exhibit its latest research and innovations in autoimmune diagnostics, including the 14-3-3η biomarker for rheumatoid arthritis (RA) and the newly launched 14-3-3η autoantibody test for axial spondyloarthritis (axSpA).

Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that ARUP Laboratories, a leading national reference laboratory in the U.S., has launched the 14-3-3η test as part of their diagnostic testing portfolio. This agreement is poised to significantly enhance the early detection and management of rheumatoid arthritis (RA), providing clinicians with an important tool to improve patient care and outcomes.

Augurex Life Sciences Corp., a world leader in the early diagnosis of autoimmune diseases and a pioneer in the field of 14-3-3η based diagnostics, today announced the appointment of Mr. Neil Klompas as President and Chief Executive Officer. Mr. Klompas will succeed Augurex’s Co-founder Dr. Norma Biln, who has served as President and CEO since the Company began operations in 2008. Dr. Biln will continue to be an integral part of the company transitioning into the interim role of global head of product research and development, and will remain on the Board of Directors as its Chair.